Newly observed thalamic involvement and mutations of the HEXA gene in a Korean patient with juvenile GM2 gangliosidosis

Metab Brain Dis. 2008 Sep;23(3):235-42. doi: 10.1007/s11011-008-9090-9. Epub 2008 Jul 23.

Abstract

Neuroimaging studies of patients with GM2 gangliosidosis are rare. The thalamus and basal ganglia are principally involved in patients affected by the infantile form of GM2 gangliosidosis. Unlike in the infantile form, in juvenile or adult type GM2 gangliosidosis, progressive cortical and cerebellar atrophy is the main abnormality seen on conventional magnetic resonance imaging (MRI); no basal ganglial or thalamic impairment were observed. This report is of a Korean girl with subacute onset, severe deficiency of hexosaminidase A activity and mutations (Arg137Term, Ala246Thr) of the HEXA gene. A 3.5-year-old girl who was previously in good health was evaluated for hypotonia and ataxia 3 months ago and showed progressive developmental deterioration, including cognitive decline. Serial brain MRI showed progressive overall volume decrease of the entire brain and thalamic atrophy. Fluorine-18 FDG PET scan showed severe decreased uptake in bilateral thalamus and diffuse cerebral cortex. We suggest, through our experience, that the thalamic involvement in MR imaging and FDG-PET can be observed in the juvenile form of GM2 gangliosidosis, and we suspect the association of mutations in the HEXA gene.

Publication types

  • Case Reports

MeSH terms

  • Ataxia / etiology
  • Brain / growth & development
  • Brain / pathology
  • Child, Preschool
  • DNA / genetics
  • Exons / genetics
  • Female
  • Fluorodeoxyglucose F18
  • Gangliosidoses, GM2 / diagnostic imaging
  • Gangliosidoses, GM2 / genetics*
  • Gangliosidoses, GM2 / pathology*
  • Humans
  • Korea
  • Magnetic Resonance Imaging
  • Muscle Hypotonia / etiology
  • Mutation / physiology*
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Thalamus / diagnostic imaging
  • Thalamus / pathology*
  • beta-Hexosaminidase alpha Chain / genetics*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • DNA
  • HEXA protein, human
  • beta-Hexosaminidase alpha Chain